Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...

The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

North Chicago, Illinois-based AbbVie Inc. (ABBV) focuses on creating medicines and solutions that address complex health issues and enhance people's lives through its core therapeutic areas ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

It's encouraging to see that AbbVie has been growing its earnings per share at 5.7% a year over the past five years. While EPS is growing at a decent rate, but future growth could be limited by ...

Piotr Swat / SOPA Images / LightRocket via Getty Images AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its purchase of Cerevel Therapeutics. The biotech company reported in November ...

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s ...

Jan 15 (Reuters) - AbbVie (ABBV.N), opens new tab plans to "commit less capital" towards experimental medicines for psychiatric disease, CEO Robert Michael said at an industry conference on ...

New prices aim to save billions by 2027. Vandana Singh Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal Johnson & Johnson's ...

Today, we're tracking presentations from AbbVie, UCB, WuXi AppTec and several other biopharma firms. Aside from JPM conference coverage, our reporters are making their way around town for one-on ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...